Death by a Single Cut

Yesterday at the USPTO I had the privilege of serving on the opening panel of the 12th Annual Advanced Patent Law Institute sponsored by The Texas University School of Law, Antonin Scalia Law School at George Mason University and the USPTO itself. The panel was organized and moderated by Rob Sterne and former CAFC CJ Paul Michel. It included Damon Matteo, Paul Stone, Peter Detkin and Paul Evans, all of whom are prominent, accomplished investors in innovation. Our audience of more than 200 advanced practitioners, judges, and USPTO personnel, included USPTO Director Michelle Lee. For the remainder of the two-day conference, its emphasis would be to sharpen its attendees’ legal skills. But for its first 75 minutes, patent non-investability was the panel’s sobering focus. Continue reading Death by a Single Cut

Drug Pricing and Life Science Commercialization

Federation of American Societies for Experimental Biology (FASEB) members number 125,000 including thirty health-focused societies. It is the largest coalition of biomedical research associations in the United States. Widely considered as the policy voice of biological and biomedical researchers, FASAB annually advocates for “stable and predictable” congressionally appropriated federal funding for basic life science research. Its 2017 recommendations for added congressional funding of five federal life science grant agencies highlights recent medicinal therapies flowing from their life science grants. It also states why and by how much grant funding should be increased for each agency. here. Federal funding stability and predictability enable projects already being conducted to continue and enable formation of new commercialization partnerships leading to more promising scientific discoveries through private sector investment. Continue reading Drug Pricing and Life Science Commercialization

Conference on Sec 101 and Joe Allen on Bayh-Dole, Past and Present

We attended an excellent conference at Covington & Burling this AM sponsored by Inventing America and IPWatchdog. The panels and speakers are listed below. An all-star cast gave a great performance. The first panel was moderated by Qualcomm’s Lauri Self and the second by IPW’s Gene Quinn. The morning’s focus was on the real life impacts of recent SCOTUS decisions addressing patent eligibility. After the state of developing law was ably explained by Jeff Lefstin, the panelists talked about the harms the decisions have caused and what to do about the new uncertainties haunting patent eligibility under Sec 101. The new doctrines emerging from several SCOTUS decisions are commonly referred to as Alice-Mayo eligibility .We will explain the problems in detail later. Suffice it to say for now that because commercialization occurs so early in the development sequence, every problem discussed most adversely affects research university Bayh-Dole execution. Continue reading Conference on Sec 101 and Joe Allen on Bayh-Dole, Past and Present